New mRNA vaccine aims to shield older adults from RSV
NCT ID NCT07289542
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive either a low or high dose of the vaccine or a placebo. The study measures how well the vaccine boosts antibodies and checks for safety over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABO1105 (RSV mRNA vaccine)
What this could lead to
If successful, this could lead to a new vaccine option to protect older adults from respiratory syncytial virus (RSV).
What could go wrong
This is a mid-stage trial with only 420 participants, so results may not confirm effectiveness or safety in larger populations. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baise Center For Disease Control & Prevention
Baise City, Baise, China